GlaxoSmithKline Immunosuppressant Imuran Now Available in Japan for Treating Crohn's Disease and Ulcerative Colitis.Tokyo, Japan, June 20, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - GlaxoSmithKline has received additional approval for Imuran, its proprietary immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses. im·mu·no·sup·pres·sant n. An agent that suppresses the body's immune response. , from the Ministry of Health, Labor and Welfare. Imuran tablets are now approved for the treatment of steroid-dependent Crohn's disease and steroid-dependent ulcerative colitis in the remission period. Currently available in over 100 countries worldwide, Imuran is indicated for the treatment of organ rejection in transplants. In addition, the agent is indicated for the treatment of inflammatory bowel disease inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. in 15 countries including France and Germany. In Japan, GlaxoSmithKline and UCB UCB - University of California at Berkeley Japan are co-promoting Imuran tablets. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion